BridgeBio Pharma, Inc. (BBIO) News
Filter BBIO News Items
BBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BBIO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BBIO News From Around the Web
Below are the latest news stories about BRIDGEBIO PHARMA INC that investors may wish to consider to help them evaluate BBIO as an investment opportunity.
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare ConferencePALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors |
BridgeBio price target raised to $50 from $45 at Evercore ISIEvercore ISI raised the firm’s price target on BridgeBio (BBIO) to $50 from $45 and keeps an Outperform rating on the shares following Attruby’s approval and management discussions. The firm is updating its Attruby model to reflect 100% probability of success from 95%, pricing of $244,000 per year, and the firm’s increasingly constructive view on Attruby’s label, which could help future differentiation, the analyst tells investors in a research note. Evercore thinks its model is still conservati |
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3 ATTRibute-CM study; final approval decision, typically consistent with the CHMP recommendation, is expected from the European Commission within the coming monthsAcoramidis, a near-complete (≥90%) stabilizer of transthyretin (TTR), was approved on November 22, 2024, by the U.S. Food and Drug Administration (FDA) as Attruby™ to reduce cardiovascu |
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MoreSAVA and APLT tank on pipeline and regulatory setbacks. |
BridgeBio Stock Up on FDA Approval of Cardiovascular DrugBBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises. |
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy. |
BridgeBio price target raised to $45 from $42 at BofABofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ATTR-CM. The news, arriving ahead of the November 29 PDUFA deadline, was “a win on many levels, marking the company’s evolution into a commercial entity with a label that is “best-case,” the analyst tells investors. ATTR-CM’s upside is “still underappreciated currently,” the analyst added. Published firs |
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart DrugBridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted. |
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive MarketOn Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on ATTRibute-CM Phase 3 study results, which showed that Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life. Also Read: BridgeBio Pharma’s Acoramidis S |
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe approval triggers a $500m payment to BridgeBio under a royalty funding agreement. |